|
印度南非联合进行艾滋病疫苗研究
发布时间：2010/10/27 10:33:00 来源：药品资讯网信息中心 印度和南非将启动一项关于两国常见的艾滋病病毒毒株的基础科学与疫苗的联合研究项目。
该项目在今年春天被两国政府正式批准，而且有望在2010年底之前启动。
新德里的国际遗传工程与生物技术中心主任Virander Chauhan说，这个为期5年耗资100万美元的项目将让两国的具有基础研究和艾滋病疫苗研究核心技能的5个研究组参与。
Chauhan说，一个成功的伙伴关系可能成为类似的南南合作的典范，并激励其他发展中国家走同样的道路。
南南合作是近日在印度海德拉巴举行的发展中国家科学院(TWAS)会议议程的重点，在印度总理曼莫汉•辛格出席的正式开幕式之后举行了一场关于非洲-印度合作的部长级圆桌研讨会。
Chauhan说，艾滋病病毒有约10种已知亚型或者说支系，而迄今大多数研究把重点放在了支系B上，它主要存在于欧洲和美国。但是支系C占了印度和南非艾滋病感染的约90%，这两个国家有全世界一些最高的感染率。
他说，研究最初将把重点放在设计分支C的抗体，这可能用于疫苗。
Chauhan指出，两国政府都已经对基础设施提供了巨大的投资，有足够的科学人才，而且正在参与高质量的疫苗研究。
他还提出，发展中国家应该进行高质量的基础研究，把重点放在疟疾、登革热、基孔肯雅热以及其他被忽视疾病等全球问题上。
他说，在发展中国家存在应对这些全球问题的专家技能，但是推进这类研究的强有力的合作和领导仍然缺乏。
“合作总是有用的，但是两国加起来在该领域产生的研究成果不到全球的6%，”南非比勒陀利亚大学的技术创新研究所主任Anastassios Pouris说。
“艾滋病研究的主要问题是，除了美国，工业化国家不感兴趣。如果社会期待找到治愈艾滋病的方法，日本和瑞士等国家应该增加他们在该领域的研究贡献。
 |
| 图示∶2010年12月即将出版的《中国特色医疗金鉴》登载的刘君主任及其机构 |
| |
|
|
Indian joint AIDS vaccine research in South Africa
Published: 2010/10/27 10:33:00 Source: Pharmaceutical Information Network Information Center, India and South Africa will launch a study on the two common strains of HIV vaccine basic science and joint research projects.
This spring the project was formally approved by both governments, and is expected to start before the end of 2010.
New Delhi's International Centre for Genetic Engineering and Biotechnology Center Virander Chauhan said that the 5-year project cost of $ 1,000,000 will allow the two countries have the basic and core skills of AIDS vaccine research group in 5 studies.
Chauhan said that a successful partnership could be similar to the example of South-South cooperation, and encourage other developing countries follow the same path.
South-South cooperation was held recently in Hyderabad, India Academy of developing countries (TWAS) the focus of the agenda, the Indian Prime Minister Manmohan Singh attended • After the official opening ceremony held in the debate about Africa - India's Minister of Cooperation level roundtable discussion.
Chauhan said that about 10 kinds of known HIV subtypes or clades, and so far most studies have focused on the branch B, which mainly in Europe and the United States. But the branch of C India and South Africa accounted for about 90% of HIV infections, some of the world the two countries have the highest infection rates.
He said the research will initially focus on the design of branch C antibodies, which may be used for vaccines.
Chauhan said the two governments have provided a huge infrastructure investment, there are sufficient scientific personnel, and is involved in high-quality vaccine.
He also suggested that developing countries should be of high quality basic research, focusing on malaria, dengue fever, chikungunya and other neglected diseases and other global issues.
He said the presence in developing countries respond to these global expert skills, but such studies to promote cooperation and strong leadership is still lacking.
"Cooperation is always useful, but the two together in the field research results generated by less than 6% of the world," University of Pretoria, South Africa, Technology Innovation Director of the Institute Anastassios Pouris said.
"The main problem is that AIDS research, in addition to the United States, the industrialized countries are not interested. If the community is looking to find a cure for AIDS, Japan and Switzerland and other countries should increase their research contributions in the field.
|
